MET and neoplasm: No statistically significant difference in the median PFS was observed in the intent-to-treat population (9.3 months for erlotinib plus emibetuzumab versus (vs.)9.5 months for erlotinib; hazard ratio (HR) = 0.89; 95% confidence interval (CI): 0.64–1.23), but high MET expression (MET 3+ (positive) in ≥ 90% of tumor cells) was shown to be related to poor prognosis, with an improvement of 15.3 months observed in the median PFS in the erlotinib plus emibetuzumab group.